Vijaya Diagnostic Acquires Arya Wellness Centre in Guwahati for ₹46 Cr, Expands to North-East
Vijaya Diagnostic Centre acquired Arya Wellness Centre in Guwahati for ~₹46 Cr, marking its entry into North-East India. The B2C-focused diagnostic centre reported FY26 revenue of ~₹26 Cr. The acquisition is expected to be EPS accretive and aims to strengthen Vijaya's eastern India presence.
The acquisition represents a significant strategic move into a new geographical region (North-East India), expanding the company's operational footprint and market presence.
The acquisition is a strategic expansion into a new region, aligning with the company's growth strategy and expected to be EPS accretive, indicating a positive development for the company.
Vijaya Diagnostic Centre Limited has announced the 100% acquisition of Arya Wellness Centre, an integrated diagnostic business in Guwahati, Assam, through a Business Transfer Agreement (BTA). The transaction, valued at approximately ₹46 crore, marks Vijaya's entry into the North-East India diagnostics market.
The acquisition is expected to close within approximately three months, subject to customary conditions precedent. This strategic move aligns with Vijaya's long-term growth strategy, focusing on B2C businesses and geographic expansion, complementing its existing presence in West Bengal and establishing a platform for further regional growth.
Arya Wellness Centre, established in 2021 as a joint venture, offers comprehensive radiology and pathology services. In FY26, it recorded revenue from operations of approximately ₹26 crore, with IND AS EBITDA of ₹5.6 crore and IND AS Adjusted PAT of ₹2.5 crore. The business generates over 85% of its revenue from the B2C segment.
Ms. Suprita Reddy, Managing Director & CEO, stated that the Guwahati acquisition is a significant milestone, extending Vijaya's reach into a market with strong demand for advanced diagnostic services. Mr. Narasimha Raju KA, CFO, added that the transaction is expected to be EPS accretive from the outset and was concluded at a valuation of approximately 8–9x of FY26 IND AS EBITDA. Mr. Siva Rama Raju Vegesna, COO, emphasized the focus on a seamless transition and maintaining service quality.
What to do with a filing like this
Vijaya Diagnostic Centre Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vijaya Diagnostic Centre Limited. Read the original for the full detail.